image credit: Pexels

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

June 20, 2024


Skyrizi (risankizumab) was previously already cleared by the FDA for adults with moderately to severely active Crohn’s disease, active psoriatic arthritis, and moderate to severe plaque psoriasis.

The approval in UC is based on the results of a 12-week induction study called INSPIRE and a 52-week maintenance study called COMMAND.

The new use in adults with moderately to severely active UC makes the drug an option for some of the million or so people in the US living with UC and is a boost to AbbVie’s efforts to grow Skyrizi as it faces a fall in sales of immunology blockbuster Humira (adalimumab), now facing biosimilar competition.

Read More on Pharmaphorum